DelveInsight’s, “Erosive Esophagitis – Pipeline Insights, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Erosive Esophagitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Erosive Esophagitis: Overview
Erosive Esophagitis (EE) is characterized by erosions in the gastric mucosa caused by acidic reflux of stomach contents into the esophagus. EE is a major type of gastroesophageal reflux disease (GERD). The causes of esophagitis include stomach acids backing up into the esophagus, infection, oral medications and allergies. Esophagitis can also lead to complications such as scarring or narrowing of the esophagus, and difficulty in swallowing and inadequately treated EE may progress to more severe diseases including Barrett’s esophagus and esophageal cancer. There are estimated to be over 65 million individuals with GERD in the U.S., of which approximately 30% have Erosive Esophagitis.
The symptoms of Erosive Esophagitis include:
A diagnosis of Erosive Esophagitis is based upon a thorough clinical evaluation and physical examination. Tests like Barium X-ray and Endoscopy are done. Laboratory tests are done to check for Infectious esophagitis. Biopsy of the inflamed tissue is also performed in order to examine the severity of the condition.
Treatment for Erosive Esophagitis is based on treating the underlying cause of disorder, use of therapies intended to lessen symptoms, and to manage complications. Medications involved over-the-counter treatments like antacids (Maalox, Mylanta etc.), H-2-receptor blockers, such as cimetidine and ranitidine, proton pump inhibitors, such as lansoprazole and omeprazole, and Potassium-competitive acid blockers are used. Steroid medication are also used to treat inflammation. Anti-reflux surgery (Fundoplication) may be used when other interventions donot work.
This segment of the Erosive Esophagitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Azeloprazole is an experimental drug that is a proton pump inhibitor. It works by inhibiting hydrogen potassium adenosine triphosphatase H /K ATPase acid pump. The drug is currently under PhaseII development for the treatment of Erosive oesophagitis.
Fexuprazan is a potassium‐competitive acid pump antagonist, which reversibly blocks the proton pump that secretes gastric acids located in the cannalicular membrane. It is a next-generation of proton pump inhibitors (PPI) and is under phase 3 clinical development in Korea for patients with erosive esophagitis.
Further product details are provided in the report……..
This segment of the report provides insights about the different Erosive Esophagitis drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 3+ key companies which are developing the therapies for Erosive Esophagitis. The companies which have their Erosive Esophagitis drug candidates in the most advanced stage, i.e. phase III include, Daewoong Pharmaceutical.
DelveInsight’s report covers around 3+ products under different phases of clinical development like
Erosive Esophagitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Erosive Esophagitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Erosive Esophagitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Erosive Esophagitis drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Erosive Esophagitis: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Erosive Esophagitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Erosive Esophagitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Erosive Esophagitis Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Fexuprazan: Daewoong Pharmaceutical
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Azeloprazole: Eisai
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Erosive Esophagitis Key Companies
Erosive Esophagitis Key Products
Erosive Esophagitis- Unmet Needs
Erosive Esophagitis- Market Drivers and Barriers
Erosive Esophagitis- Future Perspectives and Conclusion
Erosive Esophagitis Analyst Views
Erosive Esophagitis Key Companies
Appendix
List of Table
Table 1 Total Products for Erosive Esophagitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Erosive Esophagitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
• Eisai
• Daewoong Pharmaceutical
• Jiangsu Aosaikang Pharmaceutical
